Prevalence of high-risk human papilloma virus infection and cervical cytological abnormalities in female Turkish patients with rheumatologic disease

Year 2022, Volume: 6 Issue: 2, 205 - 208, 01.02.2022

Cem Yalçınkaya , İbrahim Kale , Özlem Pehlivan

https://doi.org/10.28982/josam.1057510

Abstract

Background/Aim: It is believed that patients with rheumatological diseases (RDs) are more prone to infectious diseases, possibly due to both disease-related immune dysfunction and chronic inflammation, and immunosuppressive agents used in the treatment of rheumatological diseases. In this context, we aimed to evaluate the prevalence of high-risk human papillomavirus (Hr-HPV) infection and cervical cytological abnormalities in Turkish female patients with RDs and compare them with healthy controls (HCs).
Methods: 362 sexually active patients with RDs followed up between January 2014 and June 2021 were included in this cross-sectional study. Patients with RDs were classified as autoimmune and non-autoimmune groups according to seropositivity. Data of 883 age-matched HCs were used for comparison. Demographic features, cervical cytology reports of the patients and HPV test results were retrieved from hospital database. Cervical cytological abnormalities was categorized according to Bethesda 2014. Cobas assay was used for detecting and typing for Hr-HPV.
Results: The RDs group and the HCs group were similar in terms of mean age, BMI, and rate of smokers (P>0.05). Cytological evaluation was carried out in all of 362 patients with RDs (161 autoimmune and 201 non-autoimmune) and in all of 883 HCs. HPV test was applied in 286 patients with RDs and 776 of HCs. 16 (4.4%) patients with RDs and 58 (6.6%) HCs had cervical cytological abnormality. Of the patients who underwent HPV testing; 22 (7.7%) patients with RDs and 75 (9.7%) HCs had Hr-HPV. The prevalence of cervical cytologic abnormalities and Hr-HPV infection rate were similar between patient groups and HCs (P=0.186 and P=0.400, respectively).
Conclusion: It was determined that chronic systemic inflammation, which plays a role in the pathogenesis of rheumatological diseases, and immunosuppressive agents used in the treatment did not increase the prevalence of Hr-HPV infection and cervical cytological abnormalities.

Keywords

Cervix uteri, Papanicolaou test, Papillomaviridae, Rheumatologic disease

Project Number

yoktur

References

• 1. Muñoz N, Bosch FX, de Sanjosé S, Shah KV. The role of HPV in the etiology of cervical cancer. Mutat Res Mol Mech Mutagen. 1994;305:293–301.
• 2. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73.
• 3. Sawaya GF, Smith-McCune K, Kuppermann M. Cervical Cancer Screening: More Choices in 2019. JAMA. 2019;321:2018–9.
• 4. Stoler MH. New Bethesda Terminology and Evidence-Based Management Guidelines for Cervical Cytology Findings. JAMA. 2002;287:2140.
• 5. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.e1-6.
• 6. Tchetina E, Markova G. The clinical utility of gene expression examination in rheumatology. Mediterr J Rheumatol. 2017;28:116–26.
• 7. Baillet A, Gossec L, Carmona L, Wit M de, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016;75:965–73.
• 8. Kim SC, Feldman S, Moscicki A-B. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology. 2018;57 suppl_5:v26–33.
• 9. Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5:e001041.
• 10. Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007;57:619–25.
• 11. Nayar R, Wilbur DC. The Pap Test and Bethesda 2014. Acta Cytol. 2015;59:121–32.
• 12. Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, et al. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015;15:968.
• 13. Salazar KL, Duhon DJ, Olsen R, Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J Am Soc Cytopathol. 2019;8:284–92.
• 14. Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infect Agent Cancer. 2018;13:6.
• 15. Gultekin M, Kucukyildiz I, Karaca MZ, Dundar S, Boztas G, Turan SH, et al. Trends of Gynecological Cancers in Turkey: Toward Europe or Asia? Int J Gynecol Cancer. 2017;27:1525–33.
• 16. Demir ET, Ceyhan M, Simsek M, Gunduz T, Arlier S, Aytac R, et al. The prevalence of different HPV types in Turkish women with a normal Pap smear. J Med Virol. 2012;84:1242–7.
• 17. Yuce K, Pinar A, Salman MC, Alp A, Sayal B, Dogan S, et al. Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study. Arch Gynecol Obstet. 2012;286:203–8.
• 18. Dursun P, Senger SS, Arslan H, Kuşçu E, Ayhan A. Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit. BMC Infect Dis. 2009;9:191.
• 19. Al-Sherbeni HH, Fahmy AM, Sherif N. Predisposition to Cervical Atypia in Systemic Lupus Erythematosus: A Clinical and Cytopathological Study. Autoimmune Dis. 2015;2015:1–5.
• 20. Tam L-S, Chan AYK, Chan PKS, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. Arthritis Rheum. 2004;50:3619–25.
• 21. Klumb E, Pinto A, Jesus G, Araujo M, Jascone L, Gayer C, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19:1485–91.
• 22. Lee Y-H, Choe J-Y, Park S-H, Park Y-W, Lee S-S, Kang Y-M, et al. Prevalence of Human Papilloma Virus Infections and Cervical Cytological Abnormalities among Korean Women with Systemic Lupus Erythematosus. J Korean Med Sci. 2010;25:1431.
• 23. Rojo-Contreras W, Olivas-Flores E, Gamez-Nava J, Montoya-Fuentes H, Trujillo-Hernandez B, Trujillo X, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus. 2012;21:365–72.
• 24. Wadström H, Frisell T, Sparén P, Askling J, ARTIS study group. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis. 2016;75:1272–8.
• 25. Chadwick L, Kearsley-Fleet L, Brown N, BSRBR-RA Control Centre Consortium, BSRBR-RA Contributors Group, Watson KD, et al. Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology. 2019;kez277.